The EUROPEAN SCHOOL OF HEALTH ECONOMICS,  which is part of EHE SAS, is registered as "organisme de formation" in France.

It currently offers one of Europe’s most complete education programs in Health Economics of Pharmaceuticals and other Medical Interventions. This annual program lasts three times one week and takes place in spring of each year in Southern France. The next course will take place on January 18-22, February 8-12, March 8-12, 2010.

ESHE also offers offers  disease-specific weekend courses in economic evaluation.

Current Courses

1. Health Economics of Pharmaceuticals and Medical Devices 2010
   Location: Nice (Cannes) France
   Dates: January 18-22, February 8-12, March 8-12, 2010
   Deadline for registration: 2009-12-31
   
   

   The course provides participants with an understanding of health economics and in-depth knowledge of the methods of economic evaluation of pharmaceuticals and medical interventions. The program is designed for the needs of professionals in the pharmaceutical, medical device and diagnostics industry involved in the development of reimbursement dossiers and follow-up studies, as well as for government agencies and other organisations involved in health care decisions.  Participation is limited to ~24. Each year, between 20-24 of the international faculty below,as well as additional speakers from the pharmaceutical and device industry, join the course:
   Andrew Briggs                   Institute for Health Sciences, University of Oxford, UK
   Martin Buxton                    Brunel University, London, UK
   Michael Drummond           Centre for Health Economics, University of York, UK
   Tony Culyer                       Department of Economics, University of York, UK
   Audun Hågå                       SLK - Medicines Control Agency, Oslo, Norway
   Bengt Jönsson                    Stockholm School of Economics, Stockholm, Sweden
   Linus Jönsson                     I3/Innovus, Stockholm, Sweden
   Dirk Kars                           Simon & Kucher, Bonn, Germany
   Gisela Kobelt                      European Health Economics, Mulhouse, France
   Eckhard Kucher                  Simon & Kucher, Bonn, Germany
   Claude Le Pen                   Université Dauphine, Paris, France
   Gérard de Pouvourville         ESSEC, Paris, France
   Peter Lindgren                    I3/Innovus, Stockholm, Sweden
   Thomas Lönngren               Director, EMEA, London, UK
   Alan Lyles                         John Hopkins University, Baltimore, USA
   Lorenzo Mantovani              University of Naples, Italy
   Francesco Mennini              University of Rome Tor Vergata, Italy 
   Sören Olofsson                   Southern Region (County Council), Sweden
   Frans Rutten                     Erasmus University Rotterdam, Netherlands
   Matthias v.d. Schulenburg    University of Hannover, Germany
   Ann-Christine Taubermann   LFN-Pharmaceutical Review Board, Stockholm, Sweden
   Adrian Towse                     Office of Health Economics, London, UK
   Rosario Trindade                 INFARMED, Lisbon, Portugal 

   The course combines lectures, discussions and group work. A large number of case studies will allow participants to get and share experience throughout the course.

   Week 1 - Health care in an international perspective, reimbursement systems, health care reform, health economic theory, economic evaluation, costing theory and practice, cost of illness studies, the need for modelling, models (decision trees), economic evaluation within clinical trials, international transfer of economic data, guidelines for economic evaluation, computer modelling(1). W

   Week 2 - Activities during the product life cycle, economic study protocols, outcome assessment (quality of life, utility), cost-benefit anaysis, willingness to pay studies, models (Markov models), computer modelling (2), economic evaluation in different markets, examples of economic evaluations, working in health economic departments in the industry.

   Week 3 - Statistics in economic evaluation, economic evaluation in different markets, European aspects of reimbursement, pricing in a global market, working in a reimbursement agency, the future of the pharmaceutical and biotech industry, European industrial policy, health technology assessment (the case of NICE)

    
   Get more information about the course(PDF file)
   

   ---

Previous Courses

Here you can seen list of all previous courses and the list of participants.
If you would like to contact participants for information about the course,
go to List of Previous Courses and List of participants.